Clinical trials: Alzheimer Blood Biomarkers
Alzheimer Disease
Wearables-and Blood-based Biomarkers-incorporated Modernisation of Circadian Rhythm Disruption Management in People Living With Alzheimer's Dementia: A Stepwise Study From Digital Inclusivity, Digital Therapy, to Digital Phenotyping and Biomarker Exploration
By 2025, Taiwan will become a super-aged society, with the number of Alzheimer's disease patients continuing to rise. However, the vast majority of dementia patients experience "behavioral and psychological symptoms of dementia"…
- Trial name
- NCT07222449
- Testing
- Photobiomodulation
- Where
- Taiwan
- Volunteers
- 162 people
- Sponsor
- China Medical University Hospital
Alzheimer Disease, Cognitive Dysfunction, Cognitive Disorder
DIV-AD BARCELONA: Alzheimer's Blood-Based Biomakers for a Diverse Community
The DIV-AD study aims to find out whether levels of Alzheimer's disease markers in blood differ among the main ethnical groups living in central Barcelona.
- Conditions
- Alzheimer Disease, Cognitive Dysfunction, Cognitive Disorder, Dementia, Neurodegenerative Disease
- Trial name
- DIV-AD (NCT07521722)
- Where
- Spain
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Alzheimer's Disease
A Pilot Study of Inflammatory Markers in Alzheimer's Disease
The purpose of this study is to examine the cerebrospinal fluid (CSF) of patients with Alzheimer's disease for biomarkers of inflammation and their response to the antibiotics doxycycline and rifampin.
- Trial name
- NCT00715858
- Testing
- doxycycline, rifampin
- Where
- Canada
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- McMaster University
Preclinical Alzheimer's Disease, Alzheimer's Disease (AD)
Alzheimer's Plasma Extension
The goal of this observational study is to learn how Alzheimer's disease-related blood biomarkers, brain amyloid, and memory and thinking abilities change over time.
- Trial name
- APEX (NCT06416072)
- Testing
- NAV4694
- Where
- 56 sites in United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Alzheimer Disease (AD), Cognitive Decline
Establishing Clinical Utility Evidence for a Novel Alzheimer's Disease Blood-Based Biomarker Assay
This is a national-level research study of neurologists and dementia specialists. The purpose of this study is to assess the clinical evaluation and management recommendations made by practicing providers for patient simulations…
- Trial name
- NCT07099001
- Testing
- Educational materials on the Alzheimer's disease assay, Alzheimer's disease assay results
- Where
- United States
- Volunteers
- 178 people
- Sponsor
- Qure Healthcare, LLC
Alzheimers Disease
Clinical Utility of Early vs. Late Blood Biomarker Testing for Alzheimer's Disease
The goal of this study is to evaluate whether use of the PrecivityAD2 blood biomarker assay with early result disclosure along with discretionary Precivity-ApoE proteotype testing will shorten the time to Alzheimer's Disease or…
- Trial name
- ADELAIDE (NCT06856681)
- Testing
- PrecivityAD2 - Early Testing, PrecivityAD2 - Delayed Testing
- Sponsor
- C2N Diagnostics
Alzheimer Blood Biomarkers
Diagnostic Performance of Plasma Biomarkers of Alzheimer's Disease Compared With CSF Markers
.The goal of this interventional study is to estimate the diagnostic performance of plasma biomarkers of interest (Aβ40 and Aβ42, P-Tau and NFL), enabling discrimination between patients with and without a pathophysiological AD…
- Trial name
- PLASM-ALZ (NCT06304129)
- Testing
- Blood ponction
- Where
- France
- Volunteers
- 189 people
- Sponsor
- Central Hospital, Nancy, France
Alzheimer Disease
Blood Biomarker of Alzheimer's Disease (AD)
Currently, no cures or disease modifying therapies exist for Alzheimer's disease (AD). This is partially due to the inability to detect the disease before it has progressed to a stage where there are clinical manifestations.
- Trial name
- NCT03340571
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Duke University
Mild Cognitive Impairment, Alzheimer's Disease
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss
- Trial name
- Bio-Hermes-002 (NCT06584357)
- Testing
- Biomarker Data Collection, MK6240
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- GAP Innovations, PBC
Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD)
Predicting Pre-dementia
The goal of this observational study is to learn how well a multimodal "Progression and Risk" (PR) model can predict and stage early mild cognitive impairment (MCI) due to Alzheimer's disease in cognitively normal or very mildly…
- Conditions
- Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD), Alzheimer Disease (AD), APOE-4 Positive
- Trial name
- NCT07516119
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Prevention Research Consortium Corp.
Alzheimer Disease, Dementia
Exploratory Clinical Study and Validation of Blood Biomarkers for Alzheimer's Disease
This is a 24-month, monocentric, exploratory and observational clinical study aimed at developing and validating a blood-based diagnostic test for Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease, Dementia, Neurodegenerative Disorders, Cognitive Decline
- Trial name
- ADKIT (NCT07294586)
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Alzheimer Disease, Mild Cognitive Impairment
Validation of Blood Biomarkers for Alzheimer's Disease
Alzheimer's disease (AD) has gradually become one of the major global public health issues due to its prevalence, which increases with age and life expectancy, and the economic cost of caring for patients whose cognitive decline…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia, Tauopathies
- Trial name
- ALZAN (NCT05427448)
- Testing
- Measurement of amyloid and pTau blood biomarkers
- Where
- 3 sites in France
- Volunteers
- 342 people
- Sponsor
- University Hospital, Montpellier
Alzheimer Disease
Davos Alzheimer's Collaborative Study: Sequential Administration of Digital Testing To Screen For Cognitive Impairment Followed By Blood Based Biomarkers To Assist With Timely Detection And Accurate Diagnosis Of Alzheimer's Disease
The purpose of this study is to investigate how we can detect Alzheimer's disease early by using an online memory test and a simple blood test.
- Trial name
- DAC (NCT05379348)
- Testing
- Cognitive Assessment
- Where
- United States
- Volunteers
- 1,423 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
Alzheimer Disease
An Observational Study on Lecanemab Treatment for Early Alzheimer's Disease
The goal of this observational study is to valuate the sensitivity and specificity of different blood biomarkers for monitoring and assessing Aβ-PET-confirmed mitigation of amyloid pathology by lencanumab treatment in subjects…
- Trial name
- NCT07153848
- Where
- 2 sites in China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Zhejiang University
Mild Cognitive Impairment, Alzheimer Disease
Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers
This study evaluates a diagnostic screening solution for Alzheimer's disease (AD) using digital cognitive assessments and blood-based biomarkers.
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Dementia
- Trial name
- NCT07041450
- Testing
- Digital MoCA, XpressO, MoCA
- Where
- Canada
- Volunteers
- 500 people
- Sponsor
- MoCA Clinic and Institute
Alzheimer's Disease
A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology
The primary purpose of this study is to identify participants with or without symptoms of Alzheimer's Disease (AD) that are at high risk for brain amyloid pathology using blood-based biomarkers.
- Trial name
- NCT06043700
- Testing
- No Intervention
- Where
- 3 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Eisai Limited
Alzheimer Disease, Mild Cognitive Impairment (MCI)
Biomarker-based Trial of NPC-1 for Alzheimer's Pathology
This early phase, open label, single arm clinical trial will determine the intraindividual safety, tolerability and effects of NPC1 (parthenolide and ipriflavone) on blood-based biomarkers of Alzheimer's disease (AD) pathology…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD)
- Trial name
- NPC1-AD (NCT07236190)
- Testing
- natural product combination-1 (NPC1)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Dementia Alzheimers
Blood-based Biomarkers for Diagnosis of Alzheimer's
Alzheimer's disease (AD) may currently be diagnosed using molecular biomarkers in cerebrospinal fluid (CSF) and/or positron emission tomography (PET).
- Trial name
- NCT05187819
- Testing
- predictive value of a blood test
- Where
- Norway
- Volunteers
- 300 people
- Sponsor
- Helse Stavanger HF
Alzheimer Disease, Mild Cognitive Impairment
Novel Diagnostic and Disease Stage Biomarkers in AD
This study will investigate the efficacy of novel biomarkers, namely blood-based biomarkers, pupillometry and actigraphy to track and predict progression of Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Neuro-Degenerative Diseases, Vascular Dementia
- Trial name
- TRACK-AD (NCT05175664)
- Testing
- Long-term study, Short-term study, Cross-sectional study
- Where
- Denmark
- Volunteers
- 350 people
- Sponsor
- Danish Dementia Research Centre
Alzheimer Disease
Blood Biomarkers from Internal Jugular Vein for the Diagnosis of Alzheimer's Disease
The goal of this observational study is to explore the diagnostic performance of blood biomarkers from the internal jugular vein for the diagnosis of Alzheimer's disease (AD) in patients with cognitive symptoms or concerns.
- Trial name
- NCT06754254
- Testing
- blood biomarkers from the internal jugular vein
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University